Hugel partners with Derma Dream to launch botulinum toxin product in Brazil

BRAZIL – Hugel Inc., a leading global medical aesthetics company, has expanded in Latin America by securing a strategic distribution agreement with Derma Dream, a leading aesthetic company in Brazil, for its botulinum toxin product, Letybo. 

This partnership leverages Derma Dream’s strong sales, marketing, and educational network to distribute and promote Letybo across Brazil, targeting one of the largest aesthetics markets in the region. 

Hugel official stated, “We are pleased to strengthen Letybo’s footprint through collaboration with Derma Dream, the best local partner in Brazil – the world’s third-largest aesthetics market by country.”

“By leveraging our product’s proven quality and comprehensive academic and training programs, we aim to position Letybo as a trusted premium botulinum toxin choice for both consumers and medical professionals in Brazil.” 

Pre-launch events in Rio de Janeiro and São Paulo in early September 2025 showcased Letybo’s advanced clinical data and procedural techniques to dermatologists, dentists, and biotech professionals, further solidifying the brand’s presence in the market.

Hugel, headquartered in South Korea, is a global leader in medical aesthetics with regulatory approvals in the US, China, and Europe, and operates in approximately 70 countries. 

This expansion into Brazil marks a significant milestone, positioning Letybo as a premium botulinum toxin choice through comprehensive training and collaborative marketing efforts with Derma Dream. 

This move follows Hugel’s recent announcement of the launch of its premium botulinum toxin product, Letybo, in Malaysia, marking a key step in expanding its presence in Southeast Asia. 

The launch took place during the Aesthetic Medicine & Surgery Conference & Exhibition (AMSC), Malaysia’s most significant medical aesthetics event, held from August 6 to 7, 2025.

This was followed by a brand launch event and hands-on workshop on August 8 at The Zenith Hotel Kuantan, attended by around 100 local medical professionals. 

The workshop focused on advanced botulinum toxin injection techniques, integrating anatomical understanding with clinical expertise.

Hugel executed the expansion through its long-standing Malaysian partner Venusys Medical, a distributor serving Malaysia and Singapore, aiming to solidify Letybo’s position as a premium toxin brand in the emerging Malaysian market. 

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.